LinkMed’s new share issue heavily oversubscribed

Calculation of the outcome of the new share issue implemented by LinkMed shows that the issue was oversubscribed by 41 percent, which means that the guarantee commitments entered into need not be utilized. As a result of the new share issue, LinkMed will receive approximately SEK 91.3 million, before issue expenses.

Of the new share issue, 98.5 percent, corresponding to 7,192,444 shares, were subscribed for on the basis of subscription rights. Applications to subscribe for shares without the support of subscription rights were made for approximately 42.7 percent of the issue, equivalent to 3,118,527 shares. New shares subscribed for without the support of subscription rights were allotted to shareholders who had subscribed for shares on the basis of subscription rights, in accordance with the principles stated in the prospectus published on May 12, 2009. A statement will be sent on or around June 10, 2009 confirming allotment of new shares to those subscribers who subscribed for new shares without the support of subscription rights. “Naturally, we are very pleased that such great interest was shown in LinkMed. The new share issue will give us the opportunity to create a well-positioned and profitable transplantation sector company by combining AbSorber and Olerup, in which the first steps may be a joint sales organization and the coordination of the resources of the two companies. We also now have the opportunity to continue to support the development of BioResonator, Biovator, Likvor and Ortoviva, all of which are at very interesting stages, with products close to market launch,” said Ingemar Lagerlöf, CEO LinkMed. As a result of the new share issue, the number of LinkMed shares will increase by 7,300,873 to 16,061,921 shares. Share capital will increase by SEK 7,300,873 to SEK 16,061,921. Paid subscription shares (”BTAs”) will be traded on NASDAQ OMX Stockholm until partial registration of the new shares with the Swedish Companies Registration Office has been effected. Only first class BTAs will be traded on NASDAQ OMX Stockholm. New shares subscribed to on the basis of subscription rights are expected to become subject to trading on NASDAQ OMX Stockholm on June 17, 2009. Shares subscribed to without preferential rights are expected to become subject to trading at the beginning of July 2009. Changes among the company’s principal shareholders have occurred in conjunction with the new share issue. An updated list of the 15 largest shareholders will be published on LinkMed’s website upon completion of the issue. Financial and legal advisors Swedbank Markets is LinkMed’s financial advisor and Advokatfirman Lindahl is the company’s legal advisor. For more information please contact: Ingemar Lagerlöf, CEO: +46 8 508 939 93 Okee Williams, Portfolio Manager +46 8 508 939 40 Visit LinkMed’s website: www.linkmed.se